• Latest Posts

10 immunotherapy companies making waves in 2023

Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline

Astellas menopause study meets endpoints but leukemia drug disappoints

How the microbiome can predict cancer immunotherapy success

Twisted blood vessels reveal cancer treatment success potential

Beyond Biotech podcast 37: Natural killer cells, biopharma revenue, toxic shock syndrome vaccine

ADVERTISEMENT

Research looks to make drug appear like brain tumor ‘food’

New bone cancer drug could save children’s lives

Debiopharm adds to oncology pipeline

Partnership formed to develop miRNA to treat pancreatic cancer

Peter MacCallum Cancer Centre and Cartherics to work on CAR-T cell therapy for ovarian cancer

ADVERTISEMENT